2. The number of patients with METASTATIC MELANOMA Stage IV (advanced or metastatic), treated in the last 6 months with the following:
Ipilimumab (Yervoy)
Nivolumab (Opdivo)
Ipilimumab AND Nivolumab
Pembrolizumab (Keytruda)
Vemurafenib (Zelboraf)
Vemurafenib AND Cobimetinib
Dabrafenib (Taflinar)
Trametinib (Mekinist)
Dabrafenib AND trametinib
Dacarbazine (DTIC)
For the period 1/1/2016-30/06/2016